Correlation of Apo B-48 and Apo B-100 with Oxidized LDL in Men with Central Obesity

Maria Diah Fibriani, Andi Wijaya, Burhanuddin Bahar


BACKGROUND: Obesity has a central role in the metabolic syndrome, which raises the risk for atherosclerotic cardiovascular disease (ASVCD). Apo B-48 and Apo B-100 are the necessary structural proteins required for the assembly and secretion of chylomicron and VLDL which have role in atherogenesis. The key initiating process in atherogenesis is the subendothelial retention of apolipoprotein B-containing lipoproteins. Oxidation of LDL is a hallmark of atherosclerosis development. The aim of this study was to asses the association between Apo B-48 and Apo B-100 with Oxidized-LDL as marker of atherosclerosis risk in central obesity. We hope that the result of this study can help to make a new strategy for the prevention and treatment of vascular disease.

RESULTS: There were 68 patients aged 39.6±7.3 years, Apo B-48 concentration was 7.47±5.36 μg/mL, Apo B-100 was 117.26±25.74 mg/dL, and ox-LDL was 137.05±18.88 U/L. This study showed a significant correlation between Apo B-100 and ox-LDL (r=0.608, p<0.05) and correlation between Apo B-48 and ox-LDL (r=0.171, p<0.05). The levels of Apo B-100 were significantly different between obese with Mets and obese without Mets individuals (p<0.05).

CONCLUSIONS: This study suggested that Apo B-100 concentration increase in obese in Mets as compared with obese without Mets. Apo B-48 and Apo B-100 were correlated with Oxidized LDL, but correlation between Apo B-100 and ox-LDL more significant that Apo B-48and ox-LDL.

KEYWORDS: obesity, atherogenesis, Apo B-48, Apo B-100, ox-LDL

Full Text:



International Diabetes Federation. Consensus on the Metabolic Syndrome: Definition and Treatment. Berlin: IDF; 2005.

Weinbrenner T, Schroder H, Escurriol V, Fito M, Elosua R., Vila J, et al. Circulating ox-LDL is associated with increased waist circumference independent of body mass index in men and women. Am J Clin Nutr. 2006; 83: 30-5, PMID.

Rizzo M, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev. 2007; 23: 14-20, CrossRef.

Heeren J, Beisiegel U. Intracellular metabolism of triglyceride-rich lipoproteins. Curr Opin Lipidol. 2001; 12: 255-60, CrossRef.

Ginsberg HN. New perspectives on atherogenesis, role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002; 106: 2137-42, CrossRef.

Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990; 82: 1574-94, CrossRef.

Whitfield AJ, Barret HR, Bockxmeer MV, Burnett JR. Lipid disorders and mutation in the ApoB gene. Clinchem. 2004; 50: 1725-32, CrossRef.

Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Circulation. 2007; 116: 1832-44, CrossRef.

Gustafsson M, Boren J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol. 2004; 15: 505-14, CrossRef.

Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of Apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis. 1998; 139: 205-22, CrossRef.

Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15: 551-61, CrossRef.

Goldberg IJ, Wagner WD, Pang L, Paka L, Curtis LK, DeLozier JA, et al. The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans. J Biol Chem. 1998; 273: 35355-61, CrossRef.

Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998; 101: 2658-64, CrossRef.

Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004; 84: 1381-478, PMID.

Onat A, Can G, Hergenç G, Yazıcı M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. International Journal of Obesity. 2007; 31: 1119-25, CrossRef.

Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y, et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. The Journal of Lipid Research. 2003; 44: 1256-62, CrossRef.

Grundy SM, Abate N. Secondary heart disease: systemic diseases and the heart obesity. Obesity. 2003; 8: 1463-8.

Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004; 89: 2601-7, CrossRef.

Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998; 98: 1487-94, CrossRef.

Proctor SD, Vine DF, Mamo JCL. Arterial retention of apolipoprotein B48 and B100-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002; 13: 461-70, CrossRef.

Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003; 91: 1173-7, CrossRef.

Sattar N, Williams K, Sniderman AD, D’Agostino R. Jr, Haffner SM. Comparison of Apo B and non-HDL cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the insulin resistance atherosclerosis study (IRAS). Circulation. 2004; 110: 2687-93, CrossRef.

Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: snalysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004; 14: 686-95, CrossRef.


Indexed by:






The Prodia Education and Research Institute